All In Biotech

Drug Trial Radar · NCT00713310

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis

Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8 g/Day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Children and Adolescents With Mildly-to-Moderately Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Apr 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

83

Actual

Start

Dec 2008

Primary completion

Mar 2011

Study completion Mar 2011

Sponsor

Lead sponsor
Warner ChilcottIndustry
Sponsor type
Industry
First posted
Jul 11, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this study is to assess the safety and efficacy of high dose and low dose Asacol administered as 400 mg delayed-release tablets given every 12 hours for 6 weeks to children and adolescents with mildly-to-moderately active ulcerative colitis.

Conditions

  • Ulcerative Colitis

Interventions

  • Asacol 400 mgDrug

    High dose: 17-\<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-\<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-\<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM

  • Asacol 400 mgDrug

    Low dose: 17-\<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-\<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-\<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat PopulationTime frame: Baseline and 6 weeks

Locations

42 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Facility

    Birmingham, Alabama

  • Research Facility

    Phoenix, Arizona

  • Research Facility

    Loma Linda, California

  • Research Facility

    San Diego, California

  • Research Facility

    San Francisco, California

  • Research Facility

    San Francisco, California

  • Research Facility

    Washington D.C., District of Columbia

  • Research Facility

    Gainesville, Florida

  • Research Facility

    Park Ridge, Illinois

  • Research Facility

    Louisville, Kentucky

  • Research Facility

    Boston, Massachusetts

  • Research Facility

    Worcester, Massachusetts

  • Research Facility

    Kansas City, Missouri

  • Research Facility

    Omaha, Nebraska

  • Research Facility

    Mays Landing, New Jersey

  • Research Facility

    Buffalo, New York

  • Research Facility

    New Hyde Park, New York

  • Research Facility

    Youngstown, Ohio

  • Research Facility

    Portland, Oregon

  • Research Facility

    Chattanooga, Tennessee

  • Research Facility

    Knoxville, Tennessee

  • Research Facility

    Fort Worth, Texas

  • Research Facility

    Houston, Texas

  • Research Facility

    San Antonio, Texas

  • Research Facility

    Norfolk, Virginia

  • Research Facility

    Huntington, West Virginia

  • Research Facility

    Halifax, Nova Scotia, Canada

  • Research Facility

    Hamilton, Ontario, Canada

  • Research Facility

    London, Ontario, Canada

  • Research Facility

    Ottawa, Ontario, Canada

  • Research Facility

    Montreal, Quebec, Canada

  • Research Site

    Rijeka, Croatia, Croatia

  • Research Site

    Zagreb, Croatia, Croatia

  • Research Site

    Bialystok, Poland, Poland

  • Research Site

    Bydgoszcz, Poland, Poland

  • Research Site

    Krakow, Poland, Poland

  • Research Site

    Lodz, Poland, Poland

  • Research Site

    Warsazawa, Poland, Poland

  • Research Site

    Wroclaw, Poland, Poland

  • Research Site

    Bucharest, Romania, Romania

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.